Ginkgo Bioworks Holdings, Inc. (DNA) Stock Forecast
DNA analyst forecast
as of October 18, 2026- Analyst consensus
- Sell 2.00 / 5 from 3 analysts
- Price target
- $8.00 average of analyst targets
- Upside to target
- −22.1% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $-0.58
- 52-week range
- $5.48 – $14.98
DNA analyst ratings
3 analystsNumber of analysts at each rating.
DNA price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
DNA earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.54 | −$0.58 | −$0.50 | — | — | 2 |
| Current fiscal year (2026) | −$2.93 | −$3.20 | −$2.66 | −$3.66 | +19.9% | 2 |
| Next fiscal year (2027) | −$2.90 | −$2.90 | −$2.90 | −$2.93 | +1.0% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
DNA revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $21.5M | $20.5M | $23.0M | −44.6% | 3 |
| Current fiscal year (2026) | $85.1M | $82.2M | $90.0M | −50.0% | 3 |
| Next fiscal year (2027) | $96.2M | $86.0M | $115.0M | +13.1% | 3 |
DNA EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
DNA revenue: reported and forecast
DNA EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.00 | −$0.58 | −$0.58 | −$0.58 | −$0.54 | — | 0 up · 0 down |
| Current fiscal year (2026) | −$3.42 | −$3.20 | −$3.20 | −$3.20 | −$2.93 | −14.3% | 1 up · 0 down |
| Next fiscal year (2027) | −$3.21 | −$3.21 | −$3.21 | −$3.21 | −$2.90 | −9.7% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
DNA earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; DNA beat in 5 of 12.
What analysts expect from DNA
3 analysts cover Ginkgo Bioworks; their consensus rating is sell (2.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $8.00, 22.1% below the latest close of $10.27. Analysts expect earnings of −$2.93 per share for 2026, +19.9% from a year earlier. For 2027 the average estimate is −$2.90 per share on revenue of $96.2 million. Ginkgo Bioworks beat the EPS estimate in 5 of the last 12 quarters.
Related: DNA income statement, DNA key metrics, DNA chart. See the DNA stock overview for the latest quote and news.
DNA forecast FAQ
What is Ginkgo Bioworks's price target?
The average analyst price target for Ginkgo Bioworks is $8.00, 22.1% below the latest close of $10.27.
Is Ginkgo Bioworks a buy, hold or sell?
Of 3 analysts covering Ginkgo Bioworks, 0 rate it a strong buy, 0 a buy, 1 a hold, 1 a sell and 1 a strong sell, a consensus of sell. Ratings are opinions, not a recommendation from Quotelinks.
What is Ginkgo Bioworks's EPS forecast?
Analysts forecast −$2.93 per share for 2026 (range −$3.20 to −$2.66); for 2027 the estimate is −$2.90.
What is Ginkgo Bioworks's revenue forecast?
The average revenue estimate for 2026 is $85.1 million, growth of −50.0%; for 2027 it is $96.2 million.
When does Ginkgo Bioworks report earnings?
Ginkgo Bioworks is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 after the market closes; the EPS estimate is $-0.58.
Does Ginkgo Bioworks usually beat earnings estimates?
Ginkgo Bioworks reported EPS at or above the analyst estimate in 5 of the last 12 quarters.